Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719131 · ClinicalTrials.gov registry record · Phase 2
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
A Phase 2 study of Unresectable Melanoma and Stage III Melanoma, sponsored by Emory University.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03719131 is a Phase 2 study of Unresectable Melanoma and Stage III Melanoma that is active but no longer recruiting, run by Emory University. The registered enrollment target is 15 participants, below the 141-participant average among 24 other Unresectable Melanoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03719131, a Phase 2 study of Unresectable Melanoma and Stage III Melanoma, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ipilimumab therapy.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- BIOLOGICAL Rituximab and Hyaluronidase Human
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-06-05 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03719131
The ClinicalTrials.gov registry entry for NCT03719131 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 141-participant average among 24 other Unresectable Melanoma trials with a reported enrollment target (89% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Unresectable Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT03719131 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03719131 about?
NCT03719131 is a clinical study titled "Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy". This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ipilimumab therapy.
What is the current status of trial NCT03719131?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-06-05. Estimated completion is 2026-06-30.
What conditions does trial NCT03719131 study?
This clinical trial studies the following conditions: Unresectable Melanoma, Stage III Melanoma, Stage IV Skin Melanoma, Cutaneous Melanoma, Stage III, Stage IIIA Skin Melanoma.
What interventions are being tested in trial NCT03719131?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Rituximab and Hyaluronidase Human (BIOLOGICAL).
Who is sponsoring clinical trial NCT03719131?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03719131 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
RECRUITING · Phase 2
-
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
RECRUITING · Phase 2
-
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.